J 2020

Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds

OZGEN, U., S. O. SENER, Karel ŠMEJKAL, Jiří VÁCLAVÍK, D. F. SENOL et. al.

Základní údaje

Originální název

Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds

Autoři

OZGEN, U., S. O. SENER, Karel ŠMEJKAL (203 Česká republika, domácí), Jiří VÁCLAVÍK (203 Česká republika, domácí), D. F. SENOL, Orhan I ERDOGAN, Emil ŠVAJDLENKA (203 Česká republika, domácí), A. C. GOREN a Milan ŽEMLIČKA (203 Česká republika, domácí)

Vydání

TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, CANKAYA-ANKARA, TURKISH PHARMACISTS ASSOC, 2020, 1304-530X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Turecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Kód RIV

RIV/00216224:14160/20:00118239

Organizační jednotka

Farmaceutická fakulta

UT WoS

000585327200011

Klíčová slova anglicky

Anticholinesterase; HPLC; isolation; Lysimachia; tyrosinase

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 24. 2. 2021 08:03, Mgr. Hana Hurtová

Anotace

V originále

Objectives: The scope of the present study was to specify the therapeutic potential for neurodegenerative diseases through evaluating cholinesterase and tyrosinase (TYR) inhibitory and antioxidant activity of Lysimachia verticillaris (LV), and to isolate the major compounds considering the most active fraction. Materials and Methods: The methanol extract (ME) of LV and the chloroform, ethyl acetate (EtOAC), and aqueous fractions obtained from it were used for biological activity and isolation studies. The ME and all fractions were tested for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and TYR inhibitory and antioxidant potentials using ELISA microtiter assays. Seven major compounds were isolated from the active EtOAC fraction by semi-preparative high performance liquid chromatography. The structures of the compounds were elucidated by several spectroscopic methods. Results: Marked AChE inhibitory activity was observed in the EtOAC fraction (6337 +/- 1.74%), BChE inhibitory activity in the ME and EtOAC fraction (85.84 +/- 3.01% and 83.82 +/- 3.93%), total phenol content in the EtOAC fraction (261.59 +/- 3.95 mg equivalent of gallic acid/1 g of extract) and total flavonoid contents in the EtOAC fraction (515.54 +/- 2.80 mg equivalent of quercetin/1 g of extract), and 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity and ferric-reducing antioxidant power values in the aqueous and EtOAC fractions (92.54 +/- 0.67%, 92.11 +/- 0.30%; 2.318 +/- 0.054, 2.224 +/- 0.091, respectively). Accordingly, the isolation studies were carried out on the EtOAC fractions. Compounds 1-7 (gallic acid, (+)-catechin, myricetin 3-O-arabinofuranoside, myricetin 3-O-alpha-rhamnopyranoside, quercetin 3-O-beta-glucopyranoside, quercetin 3-O-arabinofuranoside, and quercetin 3-O-alpha-rhamnopyranoside, respectively) were isolated from the active EtOAC fraction. Conclusion: LV may be a potential herbal source for treatment of neurodegenerative diseases based on its strong antioxidant activity and significant cholinesterase inhibition similar to that of the reference.